Peptide News Digest

#Transcend-T2d-1

2 stories

Clinical Trials · View digest

TRANSCEND-T2D-1 Simultaneously Published in The Lancet: Retatrutide Drives Up to 2.0% A1C Reduction and 16.8% Weight Loss in Type 2 Diabetes, 46% Reaching Normal A1C

The first Phase 3 retatrutide diabetes trial, TRANSCEND-T2D-1, was simultaneously published in The Lancet and presented at the June 6 symposium. In adults with type 2 diabetes inadequately controlled on lifestyle alone, retatrutide produced A1C reductions of up to 2.0 percentage points and weight loss of up to 16.8% (36.6 lbs) at 40 weeks, with up to 46% achieving a normal A1C — a threshold rare in diabetes treatment trials. Systolic blood pressure and lipid markers improved across doses.

Industry · View digest

Lilly Sets ADA 2026 Slate (June 5-8, New Orleans): Retatrutide TRANSCEND-T2D-1 Diabetes Data and Foundayo Head-to-Head Versus Oral Semaglutide

Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.